PROLOR Biotech to Present at the Lazard Capital Markets 7th Annual Healthcare Conference

NES-ZIONA, Israel, Nov. 9, 2010 /PRNewswire/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that company management will give a corporate presentation at the Lazard Capital Markets 7th Annual Healthcare Conference, to be held at the St. Regis Hotel in New York City.  The presentation is scheduled for November 17, 2010 at 9:30 AM ET.

A live webcast of the company's presentation will be available at the Investors section of PROLOR's website at http://www.prolor-biotech.com/?CategoryID=215, or at the Lazard conference website at http://www.wsw.com/webcast/lz8/pbth/.  A replay of the presentation will be available on the PROLOR website and will be archived for at least 30 days.

For more information on the conference, visit

http://www.lazardcap.com/conferenceList.aspx?tn=4&ln=3&itm=2124&lid=759.

ABOUT PROLOR BIOTECH

PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins and PROLOR is currently developing long-acting versions of human growth hormone, which is in clinical development, and interferon beta, factor VII, factor IX and erythropoietin, which are in preclinical development, as well as an anti-obesity peptide.  For more information on PROLOR, visit http://www.prolor-biotech.com.

SOURCE PROLOR Biotech, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED